Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))

Rachna T. Shroff; Mark Yarchoan; Ashley O'Connor; Denise Gallagher; Marianna L. Zahurak; Gary Rosner; Chimela Ohaji; Susan Sartorius-Mergenthaler; Rose Parkinson; Vivek Subbiah; Ralph Zinner; Nilofer S. Azad

doi:10.1038/bjc.2017.418

Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))

Rachna T. Shroff, Mark Yarchoan, Ashley O'Connor, Denise Gallagher, Marianna L. Zahurak, Gary Rosner, Chimela Ohaji, Susan Sartorius-Mergenthaler, Rose Parkinson, Vivek Subbiah, Ralph Zinner, Nilofer S. Azad

Research output: Contribution to journal › Comment/debate › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	e2
Journal	British journal of cancer
Volume	118
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2017.418
State	Published - Jan 1 2018
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1038/bjc.2017.418

Cite this

Shroff, R. T., Yarchoan, M., O'Connor, A., Gallagher, D., Zahurak, M. L., Rosner, G., Ohaji, C., Sartorius-Mergenthaler, S., Parkinson, R., Subbiah, V., Zinner, R., & Azad, N. S. (2018). Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407)). British journal of cancer, 118(2), e2. https://doi.org/10.1038/bjc.2017.418

Erratum : The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407)). / Shroff, Rachna T.; Yarchoan, Mark; O'Connor, Ashley et al.

In: British journal of cancer, Vol. 118, No. 2, 01.01.2018, p. e2.

Research output: Contribution to journal › Comment/debate › peer-review

Shroff, RT, Yarchoan, M, O'Connor, A, Gallagher, D, Zahurak, ML, Rosner, G, Ohaji, C, Sartorius-Mergenthaler, S, Parkinson, R, Subbiah, V, Zinner, R & Azad, NS 2018, 'Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))', British journal of cancer, vol. 118, no. 2, pp. e2. https://doi.org/10.1038/bjc.2017.418

@article{76909b490ba743558bb51665e67d7518,

title = "Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))",

author = "Shroff, {Rachna T.} and Mark Yarchoan and Ashley O'Connor and Denise Gallagher and Zahurak, {Marianna L.} and Gary Rosner and Chimela Ohaji and Susan Sartorius-Mergenthaler and Rose Parkinson and Vivek Subbiah and Ralph Zinner and Azad, {Nilofer S.}",

year = "2018",

month = jan,

day = "1",

doi = "10.1038/bjc.2017.418",

language = "English (US)",

volume = "118",

pages = "e2",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

TY - JOUR

T1 - Erratum

T2 - The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))

AU - Shroff, Rachna T.

AU - Yarchoan, Mark

AU - O'Connor, Ashley

AU - Gallagher, Denise

AU - Zahurak, Marianna L.

AU - Rosner, Gary

AU - Ohaji, Chimela

AU - Sartorius-Mergenthaler, Susan

AU - Parkinson, Rose

AU - Subbiah, Vivek

AU - Zinner, Ralph

AU - Azad, Nilofer S.

PY - 2018/1/1

Y1 - 2018/1/1

UR - http://www.scopus.com/inward/record.url?scp=85076685455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076685455&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.418

DO - 10.1038/bjc.2017.418

M3 - Comment/debate

C2 - 29315294

AN - SCOPUS:85076685455

SN - 0007-0920

VL - 118

SP - e2

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 2

ER -

Erratum: The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma (British journal of cancer (2017) 116 11 (1402-1407))

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this